Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study.
J Infect Dis
; 220(10): 1629-1634, 2019 10 08.
Article
in En
| MEDLINE
| ID: mdl-31504669
ABSTRACT
BACKGROUND:
It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors.METHODS:
Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r).RESULTS:
The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0; .8-1.3), remained significantly associated with CKD.CONCLUSION:
While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.Key words
Full text:
1
Database:
MEDLINE
Main subject:
HIV Infections
/
HIV Protease Inhibitors
/
Anti-HIV Agents
/
Renal Insufficiency, Chronic
Type of study:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
J Infect Dis
Year:
2019
Type:
Article
Affiliation country:
Denmark